查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012717

动物抗菌胜肽市场：按产品类型、应用和最终用户划分－2026-2032年全球市场预测

Animal Antibacterial Peptide Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物抗菌肽市值将达到 46.9 亿美元，到 2026 年将成长至 54.2 亿美元，到 2032 年将达到 146.8 亿美元，复合年增长率为 17.68%。

主要市场统计数据
基准年 2025 46.9亿美元
预计年份：2026年 54.2亿美元
预测年份 2032 146.8亿美元
复合年增长率 (%) 17.68%

以科学进步、监管变化、相关人员奖励和商业化的实际实施途径为框架，对动物抗菌肽进行策略性展望。

随着相关人员积极应对日益严重的抗生素抗药性和不断变化的法规环境，动物抗菌肽领域正迎来科学界和商业性日益关注的时期。基于胜肽的抗菌策略利用多种生物机制，具有特异性强、抗药性选择少、易于与综合动物健康计画相容等优势。胜肽合成、製剂和标靶递送技术的进步已使许多概念从科学概念验证（PoC）阶段迈向转化开发阶段，促使更多商业相关人员评估胜肽作为传统抗生素的有效替代品或补充疗法。因此，兽医、饲料生产商、水产养殖经营者和生物技术公司正在重新评估治疗方案、畜群健康经济效益和产品定位，并对胜肽解决方案独特的风险回报特征有了清晰的认识。

本文详细探讨了由合成技术的突破、诊断技术的整合以及监管认可度的提高所驱动的，重塑动物抗菌肽开发的决定性变革。

动物抗菌肽领域正经历变革性的转变，技术、监管和市场催化因素共同推动这项变革，重塑竞争格局。在技​​术层面，合成技术的创新和纯化製程的改进已基本消除了主要的製程瓶颈，使生产商能够生产出具有更高保真度和针对特定需求定制的理化性质的胜肽。同时，精准的诊断和病原体监测使得更有针对性的治疗和预防干预成为可能，从而提升了具有窄频谱或物种特异性活性且对微生物组影响最小的产品的商业性价值。

重点评估美国于 2025 年实施的累积关税措施将如何影响胜肽原料采购、契约製造决策和供应链弹性策略。

美国在2025年实施的关税措施，加剧了动物抗菌胜肽研发和商业化企业对供应链的担忧。由于胜肽的生产通常依赖特殊的原料、试剂和外包合成能力，关税政策的变化会影响筹资策略以及全球和国内生产之间的竞争格局。先前依赖低成本海外供应商的企业正在重新评估其总到岸成本、前置作业时间和库存策略，以降低关税变化带来的风险。在这些策略调整中，一些企业正在探索近岸外包，并建立冗余的供应商网络，以维持生产的连续性，并更快地应对需求波动。

基于细分市场的全面洞察，将产品类型差异、应用管道和最终用户人口统计特征与需求、配方要求和市场进入管道选择等经验数据连结。

了解市场区隔对于设计符合客户需求和技术可行性的产品系列和商业化路径至关重要。从产品类型角度分析产品，可以发现天然胜肽和合成胜肽之间有显着差异。此外，合成胜肽根据炼长可细分为长链、中炼和短链三类，每类胜肽的稳定性、效力和生产过程均有所不同。这些产品层面的特性会影响製剂选择、给药途径和成本结构，从而指导企业应将製程开发和分析表征工作重点放在哪些方面。

美洲、欧洲、中东和非洲以及亚太地区的区域商业化和监管前景决定了不同地区的采取路径和战略重点。

区域趋势对动物抗菌肽领域的监管策略、商业化时机和投资重点有显着影响。在美洲，监管机构和相关人员优先考虑合理使用抗菌药物和切实降低对抗生素的依赖性，从而创造出以可证实的动物健康效果和经济效益为导向的购买决策环境。该地区拥有众多跨国动物用药品公司和成熟的契约製造网络，这使得符合监管和临床标准的候选药物能够快速扩大生产规模，但也加剧了兽医和生产商之间的竞争。

竞争情报和企业创新资讯表明，成熟企业、生物技术创新者和製造专家如何合作推进胜肽候选药物的开发和商业化。

动物抗菌肽领域的竞争格局呈现出复杂的创新生态系统，该生态系统由成熟的动物用药品公司、新兴生物技术公司、专业肽类药物研发公司和契约製造组织组成。成熟的动物用药品公司在监管合规、分销网络和客户关係方面具有优势，当有证据支持其临床和经济价值时，可以将基于胜肽的产品整合到现有产品组合中。同时，小规模的生技公司和大学衍生公司往往是早期创新的驱动力，它们推动新型序列、递送平台和作用机制的研发，挑战着传统的治疗方法。

为产业领导者提供切实可行的策略建议，以加快证据产生、确保有韧性的供应链、儘早与监管机构接触以及製定以最终用户为中心的商业化策略。

产业领导者应优先实施一系列行动，以加速负责任地推广应用，并在管控技术和商业性风险的同时，确保先发优势。首先，投资于严谨、以结果为导向的证据生成，将受控临床试验与实际生产测试结合。这种双管齐下的方法既能证明在理想条件下的疗效，又能证明在实际运作环境中的可操作效益。其次，制定模组化製造策略，将内部关键品质属性的製造能力与提供规模和冗余的认证合约合作伙伴结合，从而降低供应风险和关税相关的干扰。

我们透明的调查方法结合了结构化的相关人员访谈、技术文献综述、监管分析和跨来源检验，从而得出可靠且可操作的结论。

本分析整合了第一手和第二手研究、技术文献综述以及与相关人员的对话，旨在建立一个基于证据的动物抗菌肽应用观点。第一手资料包括对兽医、饲料负责人、契约製造和科研人员的结构化访谈，以将技术主张与实际操作相结合，并识别该领域面临的应用障碍。第二手资料包括同行评审文献、监管指导文件和专利申请，以了解技术发展轨迹和智慧财产权主题。此外，还进行了严格的筛检，以避免依赖单一来源的商业性摘要。

综合考虑技术潜力、商业化现实和策略路径，可以指导有关动物抗菌肽的引进和投资的决策。

总之，动物抗菌肽是改善动物健康和生产永续性、同时减少对传统抗生素依赖的更广泛策略中一个极具前景且切实可行的组成部分。胜肽设计和递送方面的科学进步，以及监管机构对替代疗法更开放的态度，提高了基于胜肽的干预措施的可行性。然而，商业化成功取决于严格的安全性和有效性证据、生产规模化能力以及适应不同终端用户现有营运模式的能力。整合跨领域能力、寻求策略伙伴关係并采取完善的供应链和监管策略的组织将更有利于将科学潜力转化为商业性影响。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物抗菌胜肽市场：依产品类型划分

  • 天然来源胜肽
  • 合成胜肽
    • 长链
    • 中链
    • 短链

第九章：动物抗菌胜肽市场：依应用领域划分

  • 促进生长
  • 预防
    • 疾病预防
    • 疫苗佐剂
  • 治疗
    • 感染疾病治疗
    • 皮肤病的治疗

第十章：动物抗菌胜肽市场：依最终用户划分

  • 水产养殖场
  • 饲料生产商
    • 水产饲料
    • 牲畜饲料
  • 研究机构
    • 学术机构
    • 生技公司
  • 动物医院
    • 大型动物治疗
    • 小动物治疗

第十一章：动物抗菌胜肽市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：动物抗菌胜肽市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：动物抗菌胜肽市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国动物用抗菌胜肽市场

第十五章：中国动物用抗菌胜肽市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AB Vista Limited
  • AgroBioTek Laboratories LLC
  • Animal Medics
  • Anitox Corporation
  • Biogenesis Bago SA
  • Biosynth Ltd
  • Boehringer Ingelheim International GmbH
  • Cargill, Incorporated
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Ltd.
  • Elanco Animal Health Incorporated
  • Esco Aster Pte. Ltd.
  • Genera Inc.
  • Huvepharma SA
  • ImmuCell Corporation
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Novozymes A/S
  • Phibro Animal Health Corporation
  • Vetbiochem India Pvt Ltd.
  • Vetoquinol SA
  • Zoetis Inc.
  • Zomedica Pharmaceuticals Corp.
Product Code: MRR-4369010662C8

The Animal Antibacterial Peptide Market was valued at USD 4.69 billion in 2025 and is projected to grow to USD 5.42 billion in 2026, with a CAGR of 17.68%, reaching USD 14.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.69 billion
Estimated Year [2026] USD 5.42 billion
Forecast Year [2032] USD 14.68 billion
CAGR (%) 17.68%

A strategic orientation to animal antibacterial peptides that frames scientific advances, regulatory shifts, stakeholder incentives, and practical adoption pathways for commercialization

The animal antibacterial peptide space has entered a period of intensified scientific and commercial attention as stakeholders respond to rising antimicrobial resistance and shifting regulatory expectations. Peptide-based antimicrobial strategies draw on diverse biological mechanisms that offer specificity, reduced propensity for resistance selection, and compatibility with integrated animal health programs. Advances in peptide synthesis, formulation, and targeted delivery have moved many concepts from academic proof-of-concept to translational development, prompting a broader set of commercial actors to evaluate peptides as viable alternatives or complements to traditional antibiotics. As a result, veterinarians, feed formulators, aquaculture operators, and biotechnology firms are reassessing therapeutic protocols, herd health economics, and product positioning with a clearer appreciation for the unique risk-return profile of peptide solutions.

Transition from laboratory innovation to commercial readiness requires navigating scientific validation, manufacturing complexity, and regulatory alignment. The introduction of robust analytical methods and scalable synthesis platforms has reduced technical barriers, while simultaneous progress in adjuvant and delivery technologies has enhanced in vivo efficacy and stability. These converging trends create a window of opportunity for organizations that can integrate multidisciplinary capabilities, engage early with regulatory bodies, and design pragmatic evidence-generation strategies. Moving forward, success will hinge on translating mechanistic advantages into demonstrable animal health outcomes, operational compatibility, and commercial value propositions that resonate across diverse end users.

An in-depth exploration of the pivotal shifts reshaping animal antibacterial peptide development driven by synthesis breakthroughs, diagnostics integration, and evolving regulatory acceptance

The landscape for animal antibacterial peptides is undergoing transformative shifts driven by technological, regulatory, and market catalysts that are redefining competitive dynamics. On the technological front, synthesis innovations and improved purification processes have materially reduced key technical bottlenecks, enabling manufacturers to produce peptides with higher fidelity and tailored physicochemical properties. Concurrently, precision diagnostics and pathogen surveillance are enabling more targeted therapeutic and prophylactic interventions, which strengthens the commercial case for products that offer narrow-spectrum or species-specific activity and minimize microbiome disruption.

Regulatory attitudes are also evolving: authorities are increasingly receptive to antimicrobial alternatives that demonstrate clear animal welfare benefits and environmental advantages, provided that rigorous safety and efficacy data accompany submissions. This regulatory momentum incentivizes manufacturers to pursue structured evidence-generation programs that incorporate field trials and comparative effectiveness endpoints. In parallel, end users such as feed manufacturers and aquaculture producers are seeking solutions that integrate seamlessly with existing production systems, creating demand for formulations that are stable in feed matrices or water and deliver predictable dosing. These cumulative shifts favor organizations that adopt a systems-based approach, aligning R&D, manufacturing, and commercialization to reduce friction between product attributes and operational realities.

A focused assessment of how cumulative United States tariff measures enacted in 2025 influence peptide input sourcing, contract manufacturing decisions, and supply chain resilience strategies

United States tariff actions in 2025 have amplified supply chain considerations for organizations involved in animal antibacterial peptide development and commercialization. Because peptide production often depends on specialized raw materials, reagents, and outsourced synthesis capacity, changes in tariff policy influence procurement strategies and the relative competitiveness of global versus domestic manufacturing. Firms that previously relied on low-cost international suppliers are reassessing total landed cost, lead times, and inventory policies to mitigate exposure to tariff volatility. As these strategic adjustments occur, some organizations are exploring nearshoring or establishing redundant supplier networks to preserve continuity of production and accelerate response to demand fluctuations.

At the operational level, tariff-related cost pressures can affect decisions about vertical integration, contract manufacturing partnerships, and the location of high-value activities such as analytical testing and final formulation. Companies with flexible supply chains that can adapt sourcing, qualify alternate reagents, and adjust batch scheduling will be better positioned to absorb tariff-driven dislocations without compromising timelines for development and commercialization. Additionally, heightened attention to procurement resilience is catalyzing investments in supplier qualification, strategic inventory buffering, and contractual safeguards that reduce the risk of price shocks. Taken together, the cumulative implications of tariff shifts in 2025 underscore the need for proactive supply chain redesign, scenario planning, and a more deliberate alignment of commercial cadence with manufacturing strategy.

Comprehensive segmentation-driven insight linking product type distinctions, application pathways, and end user configurations to evidence needs, formulation imperatives, and route-to-market choices

Understanding segmentation is essential to designing product portfolios and commercialization pathways that align with customer needs and technical feasibility. When products are viewed through the lens of product type, a primary distinction emerges between naturally derived peptides and synthetic peptides, with synthetic variants further differentiated by chain length into long chain, medium chain, and short chain classes that carry distinct stability, potency, and manufacturing implications. These product-level attributes influence formulation choices, route of administration, and cost structures, and they guide where firms should focus process development and analytical characterization efforts.

Viewing the landscape by application reveals divergent evidence requirements and adoption curves. Growth promotion approaches prioritize compatibility with feed systems and predictable performance under production conditions, whereas prophylactic uses, which include disease prevention strategies and vaccination adjuvants, demand strong safety profiles and clear benefits to herd immunity or disease incidence reduction. Therapeutic applications break down into infection treatment and skin disease treatment, each needing controlled clinical evaluation and dosing strategies that accommodate variability in species, age, and health status. The interplay between application demands and product attributes determines clinical trial design, regulatory pathway selection, and the nature of claims that can be pursued.

End user segmentation highlights operational and commercialization differences across aquaculture farms, feed manufacturers, research institutes, and veterinary clinics. Feed manufacturers must reconcile compatibility with aquafeed and livestock feed formats, focusing on processing stability and uniformity of dosing, while research institutes-which span academic institutes and biotech companies-drive early-stage discovery, mechanism elucidation, and translational studies. Veterinary clinics differentiate between large animal practice and small animal practice needs, which affects dosage forms, administration routes, and practitioner training requirements. These cross-cutting segmentation dimensions underscore that product development and commercialization cannot be one-size-fits-all; instead, they require tailored evidence packages, formulation strategies, and go-to-market models calibrated to each segment's technical constraints and decision drivers.

Regional commercialization and regulatory perspectives across the Americas, Europe Middle East and Africa, and Asia-Pacific that frame differential adoption paths and strategic priorities

Regional dynamics materially shape regulatory strategy, commercialization timing, and investment priorities across the animal antibacterial peptide domain. In the Americas, regulatory bodies and industry stakeholders emphasize antimicrobial stewardship and measurable reductions in antibiotic reliance, creating an environment where demonstrable animal health outcomes and economic justification influence purchasing decisions. This region's strong presence of multinational animal health companies and established contract manufacturing networks supports rapid scale-up for candidates that clear regulatory and clinical thresholds, but it also intensifies competition for veterinarian and producer attention.

In Europe, the Middle East and Africa, regulatory frameworks tend to be heterogeneous, with European jurisdictions often setting higher bars for safety and environmental impact while other countries within the broader region may prioritize access and affordability. Manufacturers seeking to operate across these territories must reconcile disparate approval pathways and data expectations, designing evidence generation strategies that anticipate the most rigorous regulatory requirements while remaining adaptable to local commercial conditions. The Asia-Pacific region presents a different set of dynamics: rapid growth in aquaculture and intensive livestock production creates significant demand for alternatives to conventional antibiotics, and regulatory modernization in several markets is opening pathways for novel interventions. However, the Asia-Pacific landscape also emphasizes cost competitiveness and supply chain proximity, so organizations must weigh pricing strategies and local manufacturing partnerships to gain traction. Across all regions, success depends on aligning scientific validation with pragmatic commercialization approaches that respect local regulatory nuance and customer economics.

Competitive and corporate innovation intelligence showing how incumbents, biotech innovators, and manufacturing specialists collaborate to advance peptide candidates and commercial readiness

The competitive environment for animal antibacterial peptides is characterized by a mix of established animal health companies, emerging biotech players, specialized peptide developers, and contract manufacturing organizations that together create a complex innovation ecosystem. Incumbent animal health firms bring strengths in regulatory navigation, distribution networks, and customer relationships, enabling them to integrate peptide-based products into existing portfolios where evidence supports clinical and economic value. Conversely, smaller biotechnology companies and academic spinouts frequently drive early-stage innovation, advancing novel sequences, delivery platforms, and mechanism-of-action insights that disrupt conventional approaches.

Strategic partnerships and licensing arrangements are common mechanisms to bridge capability gaps and accelerate commercialization. Larger companies may form research collaborations or co-development agreements with peptide specialists to access proprietary chemistries and scalable synthesis methods, while contract development and manufacturing organizations play a pivotal role in moving candidates from bench to GMP-compliant production. Investors and corporate development teams are increasingly attentive to companies that demonstrate clear translational pathways, reproducible manufacturing processes, and defensible intellectual property around peptide sequences and formulations. Competitive differentiation frequently rests on a combination of strong clinical evidence, manufacturing robustness, and the ability to deliver practical administration formats that fit into existing animal health workflows.

Actionable strategic recommendations for industry leaders to accelerate evidence generation, secure resilient supply chains, engage regulators early, and design end user-centric commercialization strategies

Industry leaders should execute a set of prioritized actions to accelerate responsible adoption and capture first-mover advantages while managing technical and commercial risk. First, invest in rigorous, outcome-focused evidence generation that pairs controlled clinical studies with real-world production trials; this dual approach demonstrates both efficacy under ideal conditions and practical benefits under operational realities. Second, develop modular manufacturing strategies that combine in-house capabilities for critical quality attributes with qualified contract partners to provide scale and redundancy, thereby mitigating supply risk and tariff-related disruptions.

Third, build regulatory engagement plans early in development to align study designs with the most stringent expected requirements and to accelerate approvals across multiple jurisdictions. Fourth, design product formats and distribution models that minimize disruption to end users' existing workflows by emphasizing feed-compatible formulations, easy-to-administer dosing systems, and clear guidance for practitioners. Fifth, pursue strategic alliances that couple proprietary peptide technologies with distribution channels and formulation expertise, enabling faster market entry and broader adoption. Implementing these recommendations requires cross-functional governance, disciplined portfolio prioritization, and a willingness to pilot innovative commercial models that reflect the nuanced needs of different end users.

Transparent research methodology combining structured stakeholder interviews, technical literature review, regulatory analysis, and cross-source validation to ensure robust and actionable conclusions

This analysis synthesizes primary and secondary research, technical literature review, and stakeholder engagement to construct an evidence-based perspective on animal antibacterial peptides. Primary inputs included structured interviews with veterinarians, feed formulators, contract manufacturers, and research scientists to ground technical claims in operational realities and to identify adoption barriers encountered in field settings. Secondary inputs encompassed peer-reviewed literature, regulatory guidance documents, and patent filings to map technological trajectories and intellectual property themes, while careful screening avoided relying on single-source commercial summaries.

Analytical methods combined qualitative thematic analysis of interview data with comparative evaluation of regulatory frameworks across jurisdictions to highlight cross-market differences in evidence expectations. Validation occurred through triangulation across data sources and follow-up consultations with subject-matter experts to test assumptions and refine interpretations. The approach emphasized transparency in assumptions, conservative interpretation of experimental results, and clear delineation between established facts and emerging hypotheses. Wherever possible, conclusions reflect consensus views rooted in reproducible methods and corroborating technical literature, ensuring that recommendations are actionable and aligned with current scientific and regulatory realities.

Concluding synthesis that integrates technical promise, commercialization realities, and strategic pathways to guide adoption and investment decisions in animal antibacterial peptides

In conclusion, animal antibacterial peptides represent a promising and pragmatic element of a broader strategy to reduce reliance on traditional antibiotics while improving animal health outcomes and production sustainability. Scientific advances in peptide design and delivery, coupled with evolving regulatory openness to alternatives, have improved the viability of peptide-based interventions. Nonetheless, successful commercialization depends on rigorous evidence of safety and efficacy, manufacturing scalability, and the ability to fit into existing operational models across diverse end users. Organizations that integrate cross-functional capabilities, pursue strategic partnerships, and adopt deliberate supply chain and regulatory strategies will be best positioned to translate scientific potential into commercial impact.

Looking ahead, the path to widespread adoption will be incremental and evidence-driven. Early successes will likely focus on niches where peptides clearly outperform alternatives, such as targeted prophylactic applications or skin disease treatments where topical or localized delivery reduces systemic exposure. Broader adoption will follow as cost-effective manufacturing and robust clinical datasets accumulate. For stakeholders that balance scientific rigor with pragmatic commercialization planning, peptides offer a credible route to meeting stewardship goals while preserving productivity and animal welfare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Antibacterial Peptide Market, by Product Type

  • 8.1. Naturally Derived Peptide
  • 8.2. Synthetic Peptide
    • 8.2.1. Long Chain
    • 8.2.2. Medium Chain
    • 8.2.3. Short Chain

9. Animal Antibacterial Peptide Market, by Application

  • 9.1. Growth Promotion
  • 9.2. Prophylactic
    • 9.2.1. Disease Prevention
    • 9.2.2. Vaccination Adjuvant
  • 9.3. Therapeutic
    • 9.3.1. Infection Treatment
    • 9.3.2. Skin Disease Treatment

10. Animal Antibacterial Peptide Market, by End User

  • 10.1. Aquaculture Farms
  • 10.2. Feed Manufacturers
    • 10.2.1. Aquafeed
    • 10.2.2. Livestock Feed
  • 10.3. Research Institutes
    • 10.3.1. Academic Institute
    • 10.3.2. Biotech Company
  • 10.4. Veterinary Clinics
    • 10.4.1. Large Animal Practice
    • 10.4.2. Small Animal Practice

11. Animal Antibacterial Peptide Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Animal Antibacterial Peptide Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Animal Antibacterial Peptide Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Animal Antibacterial Peptide Market

15. China Animal Antibacterial Peptide Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AB Vista Limited
  • 16.6. AgroBioTek Laboratories LLC
  • 16.7. Animal Medics
  • 16.8. Anitox Corporation
  • 16.9. Biogenesis Bago S.A.
  • 16.10. Biosynth Ltd
  • 16.11. Boehringer Ingelheim International GmbH
  • 16.12. Cargill, Incorporated
  • 16.13. Dechra Pharmaceuticals PLC
  • 16.14. Eco Animal Health Ltd.
  • 16.15. Elanco Animal Health Incorporated
  • 16.16. Esco Aster Pte. Ltd.
  • 16.17. Genera Inc.
  • 16.18. Huvepharma S.A.
  • 16.19. ImmuCell Corporation
  • 16.20. Kemin Industries, Inc.
  • 16.21. Merck & Co., Inc.
  • 16.22. Neogen Corporation
  • 16.23. Novozymes A/S
  • 16.24. Phibro Animal Health Corporation
  • 16.25. Vetbiochem India Pvt Ltd.
  • 16.26. Vetoquinol S.A.
  • 16.27. Zoetis Inc.
  • 16.28. Zomedica Pharmaceuticals Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)